Selke, J.; Dzierma, Y.; Manda, K.; Hildebrandt, G.; Frerker, B.; Kalata, P.; Ackermann, C.; Bock, F.
Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Curr. Oncol. 2026, 33, 351.
https://doi.org/10.3390/curroncol33060351
AMA Style
Selke J, Dzierma Y, Manda K, Hildebrandt G, Frerker B, Kalata P, Ackermann C, Bock F.
Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Current Oncology. 2026; 33(6):351.
https://doi.org/10.3390/curroncol33060351
Chicago/Turabian Style
Selke, Janne, Yvonne Dzierma, Katrin Manda, Guido Hildebrandt, Bernd Frerker, Paul Kalata, Christin Ackermann, and Felix Bock.
2026. "Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC" Current Oncology 33, no. 6: 351.
https://doi.org/10.3390/curroncol33060351
APA Style
Selke, J., Dzierma, Y., Manda, K., Hildebrandt, G., Frerker, B., Kalata, P., Ackermann, C., & Bock, F.
(2026). Real-World Survival Outcomes Following Chemoradiotherapy with or Without Durvalumab in PD-L1-Defined Subgroups of Stage III Unresectable NSCLC. Current Oncology, 33(6), 351.
https://doi.org/10.3390/curroncol33060351
